Gapping down
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- RSKD -8.7%, BTDR -0.7%
Other news:
- COIN -1.7% (files prospectus supplement relating to resale of up to 10,997,856 Class A shares by the selling stockholders)
- NAMS -1.5% (discloses in filing that it entered into a supply agreement with A. Menarini International Licensing; Under the terms of agreement, company agreed to supply Menarini with obicetrapib monotherapy and obicetrapib and ezetimibe fixed-dose combination finished products in bulk tablet form)
- MP -1.5% (files prospectus supplement relating to offer and sale of 24,521,672 shares by the selling stockholders)
- AAPG -1.3% (Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and EMA)
- RBLX -0.9% (report SEC case concluded in May, according to Bloomberg)
- TLS -0.9% (has no current plans or needs to raise cash proceeds through the issuance of dilutive capital)
- BHVN -0.7% (files prospectus supplement relating to resale of 3,588,688 shares issued to the selling shareholder under the Knopp Amendment)